GSK (LON:GSK) Stock Rating Reaffirmed by Shore Capital

Shore Capital reissued their buy rating on shares of GSK (LON:GSK) in a research note published on Wednesday morning, Marketbeat Ratings reports.

A number of other research analysts have also weighed in on GSK. Barclays reaffirmed an equal weight rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a research note on Monday, April 8th. Deutsche Bank Aktiengesellschaft restated a buy rating and issued a GBX 1,950 ($24.49) target price on shares of GSK in a report on Wednesday, April 17th. Finally, Berenberg Bank lifted their price target on GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the company a buy rating in a research note on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of GBX 1,675.63 ($21.05).

GSK Price Performance

Shares of GSK opened at GBX 1,733.50 ($21.77) on Wednesday. The business’s fifty day moving average is GBX 1,663.28 and its 200 day moving average is GBX 1,557.96. GSK has a 12-month low of GBX 1,302.60 ($16.36) and a 12-month high of GBX 1,739.56 ($21.85). The company has a quick ratio of 0.73, a current ratio of 0.88 and a debt-to-equity ratio of 140.82. The stock has a market cap of £70.90 billion, a P/E ratio of 1,444.58, a P/E/G ratio of 1.12 and a beta of 0.27.

GSK Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, July 11th. Investors of record on Thursday, May 16th will be paid a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, May 16th. This represents a yield of 0.9%. GSK’s dividend payout ratio is 5,333.33%.

Insiders Place Their Bets

In related news, insider Urs Rohner acquired 434 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were acquired at an average price of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,060.52). In other GSK news, insider Emma Walmsley sold 139,792 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,382.19). Also, insider Urs Rohner purchased 434 shares of GSK stock in a transaction dated Wednesday, March 20th. The shares were purchased at an average price of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,060.52). Company insiders own 1.77% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.